TUCSON, Ariz., June 07, 2017 (GLOBE NEWSWIRE) — Lawrence Mehren, president and chief executive officer of Accelerate Diagnostics, will present at the 37th Annual Growth Stock Conference hosted by William Blair & Company in Chicago on Wednesday, June 14, 2017, at 04:00 PM Central Time. A live webcast of the presentation will be accessible from […]
TUCSON, Ariz., June 07, 2017 (GLOBE NEWSWIRE) — Lawrence Mehren, president and chief executive officer of Accelerate Diagnostics, will present at the 37th Annual Growth Stock Conference hosted by William Blair & Company in Chicago on Wednesday, June 14, 2017, at 04:00 PM Central Time.
A live webcast of the presentation will be accessible from the events section of the company’s investor relations website at http://acceleratediagnostics.com/investors. A replay will be available for 90 days after the conference at the same website address.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (“Accelerate Diagnostics”) (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company’s Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were recently cleared by the FDA for antimicrobial susceptibility testing direct from positive blood culture samples. The solution leverages proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. To learn more, visit http://acceleratediagnostics.com.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Certain of the statements made in this press release are forward looking, such as those, among others, about the performance and potential clinical and workflow benefits of our products, and potential of future applications of our products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2017, and in any other reports that we file with the Securities and Exchange Commission from time to time. The company’s forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
CONTACT: Investors May Contact: Laura Pierson, Accelerate Diagnostics, +1 520 365-3100 email@example.com Reporters May Contact: Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100 firstname.lastname@example.org
Source: Health Care